The FDA has broadened approval for Boston Scientific’s Watchman Flx and Flx Pro left atrial appendage closure devices to include patients following atrial fibrillation ablation procedures. This regulatory expansion extends Watchman’s clinical use beyond its original indication, supporting management of stroke risk in a larger patient population. The label update comes ahead of Boston Scientific’s upcoming quarterly earnings report, illustrating continued regulatory progress for one of its leading cardiovascular devices.